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Abstract Recent work has suggested that heroin and morphine-
6[i-glucuronide (M6G) both act through a novel mu opioid 
receptor subtype distinct from those mediating morphine's 
actions. This very high affinity 3H-M6G site is selectively 
competed by 3-methoxynaltrexone. In vivo, 3-methoxynaltrex-
one (2.5 ng, i.c.v.) selectively antagonizes the analgesic actions of 
heroin and M6G without interfering with mu (morphine and 
[D-Ala2,MePhe4,Gly(ol)5|enkephalin), delta (|D-Pen2,D-
Pen5]enkephalin), kappai (U50,488H) or kappa3 (naloxone 
benzoylhydrazone) analgesia. In dose-response studies, 3-meth-
oxynaltrexone (2.5 ng, i.c.v.) significantly shifted the ED50 
values for heroin and its active metabolite, 6-acetylmorphine, 
without affecting the morphine curve. These results indicate that 
3-methoxynaltrexone selectively blocks a novel 3H-M6G binding 
site which is responsible for the analgesic actions of heroin and 
M6G. This ability to selectively antagonize heroin actions opens 
new possibilities in the development of therapeutics for the 
treatment of opioid abuse. 
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1. Introduction 
Pharmacokinetics have long been thought to play a crucial 
role in the addictive potential of many drugs of abuse, includ-
ing heroin. Compared to morphine, heroin crosses the blood-
brain barrier far more rapidly and to a greater extent [1,2], 
leading many investigators to conclude that pharmacokinetic 
differences between the two agents were responsible for their 
different pharmacology [1,3-6]. However, evidence now sug-
gests that heroin and M6G both act through a novel receptor 
mechanism which is distinct from that of morphine [7-11]. 
Despite early evidence demonstrating its activity [12,13], the 
importance of morphine-6P-glucuronide (M6G) has only been 
recognized recently [14-16]. When given centrally to avoid the 
blood-brain barrier, M6G is 100-fold more potent than mor-
phine [14]. Despite this dramatic difference in analgesic po-
tency, morphine competes traditional mu receptor binding in 
either brain tissue or cells transfected with the MOR-1 clone 
with higher affinity than M6G. In addition, the efficacy of 
M6G in cyclase studies using MOR-1 transfected cells is not 
significantly different from morphine [17]. Thus, the extraor-
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dinary potency of M6G cannot be explained by either en-
hanced affinity or efficacy at traditional mu receptors. 
Antisense mapping studies of the MOR-1 clone, which en-
codes a mu opioid receptor, reveal very different sensitivity 
profiles for morphine and M6G [7-9,18]. A series of three 
antisense oligodeoxynucleotides targeting exon 1 of MOR-1 
effectively block morphine analgesia without affecting the ac-
tions of M6G [7-9,11]. Conversely, an additional three anti-
sense probes based upon exon 2 which are inactive against 
morphine analgesia dramatically lower M6G analgesia. An 
exon 2 antisense probe which was inactive against morphine 
also blocked the analgesic actions of both heroin and its active 
metabolite, 6-acetylmorphine [11]. Morphine analgesia also 
can be differentiated from M6G and heroin by the G-proteins 
involved in their analgesic responses [7,11,19,20]. Morphine 
analgesia is sensitive to a Gj0c2 antisense probe, but not to 
another targeting G;al. In contrast, the GiCd antisense blocks 
both M6G and heroin analgesia. 
Finally, 3H-M6G binding studies have identified a novel 
binding site with very high affinity for M6G (Kp, 68 pM) 
[17]. During the characterization of this site, we came across 
a compound which appeared to selectively compete binding to 
this M6G site. We now report that this compound, 3-meth-
oxynaltrexone, selectively competes this M6G site and antag-
onizes M6G and heroin analgesia, opening the possibility of 
novel therapeutic approaches towards the treatment of drug 
addiction. 
2. Materials and methods 
2.1. iH-M6G binding assays 
3H-M6G (85 Ci/mmol) was synthesized in our laboratory as pre-
viously described [21]. Binding was performed in mouse brain homo-
genates at 25°C for 150 min in potassium phosphate buffer (50 mM, 
pH 7.4) with MgCl2 (5 mM) and filtered over glass fiber filters [22,23]. 
Nonspecific binding was determined with levallorphan (1 uM) [17]. 
Binding was linear with tissue and reached steady-state levels within 
60 min. Binding parameters were determined using nonlinear regres-
sion analysis. 
2.2. Analgesia 
Male CD-I mice were purchased from Charles River Breeding Lab-
oratories (Raleigh, NC). Opiates were obtained from the Research 
Technology Branch of the National Institute on Drug Abuse (Rock-
ville, MD). Antinociception, referred to as 'analgesia' in the current 
study, was assessed in the tailflick assay, as previously described 
[8,11,15,24]. Baseline latencies, ranging from 2 to 3 s, were determined 
for each mouse prior to any testing. Analgesia, defined quantally as a 
doubling or greater of the baseline latency for an individual mouse, 
was determined 15 min after i.c.v. or 30 min after s.c. injection. Sig-
nificance among single doses was assessed using the Fisher Exact Test. 
ED50 values and 95% confidence limits were determined using either 
the Bliss [25] or a computerized Litchfield-Wilcoxin-derived program 
[26,27], 
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Fig. 1. Effect of 3-methoxynaltrexone on 3H-M6G binding in brain 
homogenates. 3H-M6G binding was determined in calf brain homo-
genates at various concentrations of radioligand (0.03^1 nM) alone 
or in the presence of a fixed concentration of 3-methoxynaltrexone 
(10 nM) and expressed as a Scatchard plot. Results are given from 
3 replicate experiments. Nonlinear regression analysis of the binding 
curve of 3H-M6G alone was best fit by two sites: Site (1) KD 
0.066 ±0.01 nM, Smax 7 ±1.6 fmol/mg protein; Site (2) KD 1.8 ±0.2 
nM, Smax 85 ± 7 fmol/mg protein. Inclusion of the 3-methoxynal-
trexone eliminates the higher-affinity binding component, leaving the 
lower component virtually unchanged (Kb 1.3 ±0.1 nM; Bmsa 91 ±5 
fmol/mg protein). 
3. Results 
In earlier binding studies, 3H-M6G labeled a novel high-
affinity site (Kv 68 pM) in addition to the traditional mu 
receptors. Competition experiments revealed several com-
pounds with shallow slopes which could be resolved into 
two components using nonlinear regression analysis [17]. 
One compound, 3-methoxynaltrexone, was particularly inter-
esting. With IC50 values of approximately 12 and 400 nM, 3-
methoxynaltrexone discriminated quite well between the two 
3H-M6G binding components. Its relatively poor affinity 
against the transfected mu receptor encoded by MOR-1 
(IC50 250 nM) suggested that 3-methoxynaltrexone might 
have higher affinity against the high-affinity M6G site than 
traditional mu receptors. To define more fully the selectivity 
of 3-methoxynaltrexone for the 3H-M6G binding sites, we 
performed 3H-M6G saturation studies with or without a fixed 
concentration of 3-methoxynaltrexone. The control saturation 
study yielded a curvilinear Scatchard plot similar to ones pre-
viously observed [17]. Although the lower-affinity component 
(Kb 1.8 nM) corresponded quite well to the affinity of 3H-
M6G in CHO cells transfected with MOR-1 (KB 3.3 nM) and 
to K\ values determined from competition studies against mu 
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Fig. 2. Inhibition of opioid analgesia by 3-methoxynaltrexone. 
Groups of mice (»a 10) received a fixed dose of morphine (0.7 ug, 
i.c.v.), M6G (12.5 ng, i.c.v.), 6-acetylmorphine (1.2 (xg, i.c.v.) or 
DAMGO (8 ng, i.c.v.) and the indicated dose of 3-methoxynaltrex-
one (i.c.v.). Analgesia was determined and expressed as the percent 
of mice responding. At 2.5 ng, 3-methoxynaltrexone significantly 
lowers the analgesic actions of both M6G (P<0.01) and 6-acetyl-
morphine (P<0.01), but not either morphine or DAMGO. 
binding in brain [14], the high-affinity binding component (KB 
66 pM) was unique. Including a fixed concentration of 3-
methoxynaltrexone (10 nM), a concentration far below its 
IC50 value against traditional mu binding, eliminated the 
high-affinity component of 3H-M6G binding (Fig. 1), indicat-
ing that both 3-methoxynaltrexone and M6G bound with 
highest affinity to the same site. 
CXBK are insensitive to morphine given systemically or 
intracerebroventricularly [28-30], which readily distinguishes 
them from CD-I mice which are responsive to a wide variety 
of opioid analgesics (Table 1). Given intracerebroventricu-
larly, morphine at a dose 15-fold higher than the ED5o value 
in CD-I mice is analgesic in less then 25% of mice, a differ-
ence which is particularly dramatic at 0.7 u,g, i.c.v., where the 
response in CD-I mice (70%) is significantly different from 
that in the CXBK mice (8%, P< 0.0001). In contrast to mor-
phine, CXBK mice display the same sensitivity as CD-I mice 
to M6G, heroin and 6-acetylmorphine, the active metabolite 
of heroin (Table 1). Thus, M6G and heroin analgesia in 
CXBK mice involves mechanisms distinct from morphine an-
algesia, consistent with a novel heroin/M6G receptor. 
Naltrexone is a potent opioid antagonist, raising the possi-
bility that 3-methoxynaltrexone also might be an antagonist. 
We therefore examined its reversal of opioid analgesia (Fig. 
2). 3-Methoxynaltrexone antagonized the analgesic actions of 
M6G and 6-acetylmorphine 3-fold more potently than either 
morphine or the mu peptide [D-Ala2,MePhe4,Gly(ol)5]enke-
phalin (DAMGO). At 2.5 ng (i.c.v.), 3-methoxynaltrexone 
significantly lowered the response of M6G, heroin and 6-ace-
Table 1 
Analgesic activity of opioids in CD-1 and CXBK mice 
Drug 
Morphine 
M6G 
Heroin 
6-Acetylmorphine 
Route 
i.c.v. 
i.c.v. 
s.c. 
i.c.v. 
ED50 value 
CD-I 
0.65 ug (0.25, 2.67) 
13.0 ng (6.1, 31.8) 
0.33 mg/kg (0.23, 0.46) 
1.76 ng (0.84, 3.7) 
CXBK 
> 1 0 u g 
10.3 ng (5.1, 22.3) 
0.41 mg/kg (0.2, 0.85) 
1.18 ng (0.89, 1.5) 
Ratio 
>15 
0.8 
1.2 
0.7 
ED50 values with 95% confidence limits were determined from at least three doses of each drug given to groups of mice (nalO) through the 
indicated route. In the CXBK mice, the highest morphine dose tested was 10 ug, i.c.v., which was analgesic is less than 25% of mice tested. 
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Table 2 
Effect of 3-methoxynaltrexone on the analgesic actions of opioid analgesics 
Drug Analgesic ED50 (95% confidence limits) Ratio 
Control With 3-MeONtx 
Supraspinal 
6-Acetylmorphine 
M6G 
Morphine 
Systemic 
Heroin 
Morphine 
566 ng (342, 937) 
6.45 ng (4.2, 9.7) 
410 ng (269, 621) 
0.50 mg/kg (0.38, 0.67) 
3.11 mg/kg (2.4, 4.0) 
1730 ng (1443, 2074) 
18.0 ng (15, 22) 
424 ng (272, 660) 
0.94 mg/kg (0.73, 1.2) 
2.85 mg/kg (2.1, 3.9) 
3.1 ; 
2.8 ; 
1.0 
1.9 
0.9 
ED50 values were determined using groups of mice (n > 10) and three agonist doses (i.e.v.) in the presence and absence of a fixed 3-methoxynal-
trexone dose (2.5 ng, i.e.v.). All agonists were given through the indicated route of administration and results are the ED50 with 95% confidence 
limits. 3-Methoxynaltrexone significantly shifts the dose-response curves for 6-acetylmorphine, M6G and heroin (P<0.05). 
tylmorphine (i '<0.03) (Fig. 3). In contrast, the same 3-me-
thoxynaltrexone dose was inactive against the analgesic ac-
tions of morphine, the mu peptide DAMGO, the delta anal-
gesic [D-Pen2,D-Pen5]enkephalin (DPDPE), the kappai drug 
U50,488H or the kappa3 analgesic, naloxone benzoylhydra-
zone (NalBzoH; Fig. 3). Dose-response curves for supraspi-
nal morphine, M6G and 6-acetylmorphine analgesia in the 
absence and presence of 3-methoxynaltrexone (2.5 ng, i.c.v.) 
revealed significant shifts of approximately 3-fold for M6G 
and for 6-acetylmorphine (P < 0.05) while the morphine 
dose-response curve remained unchanged (Table 2). The 
same 3-methoxynaltrexone dose also shifted the dose-re-
sponse curve for systemically administered heroin but not 
for morphine. 
4. Discussion 
In addition to traditional mu receptors, 3H-M6G labels 
with very high affinity a unique site with a low abundance 
in brain which appears to be selective for M6G [17]. In these 
studies, 3-methoxynaltrexone lowers 3H-M6G binding with a 
shallow competition curve and nonlinear regression analysis 
indicated widely differing affinities for two 3H-M6G binding 
components. The current studies confirm that 3-methoxynal-
■a s 
Fig. 3. Effect of 3-methoxynaltrexone on the dose-response curves 
of opioid analgesics. Left: Groups of mice (nalO) received mor-
phine (0.7 ug, i.c.v.), DPDPE (8 ug, i.c.v.), NalBzoH (20 ug, i.c.v.), 
U50,488H (75 ng, i.c.v.), M6G (12.5 ng, i.c.v.) or 6-acetylmorphine 
(1.2 u.g, i.c.v.) alone or with 3-methoxynaltrexone (2.5 ng, i.c.v.). 
Right: Groups of mice (na 10) received morphine (5 mg/kg, s.c.) or 
heroin (0.8 mg/kg, s.c.) alone or with 3-methoxynaltrexone (2.5 ng, 
i.c.v.). Analgesia was determined and expressed as the percent of 
mice responding. 
trexone and 3H-M6G both bind with highest affinity to the 
same site. Methylating the 3-hydroxyl group lowers the affin-
ity of opioids for traditional mu receptors, as illustrated by 
codeine and oxycodone. Thus, the poor affinity of 3-meth-
oxynaltrexone for traditional mu receptors was expected. 
However, this structural change does not affect binding to 
the M6G site to the same degree. 
Like naltrexone, 3-methoxynaltrexone is an antagonist. It 
potently blocks the analgesic actions of a wide variety of mu 
analgesics. However, it shows a significant selectivity for M6G 
and heroin, antagonizing the actions of both analgesics at a 
dose which was inactive against morphine and the mu peptide, 
DAMGO. The selectivity of 3-methoxynaltrexone for M6G 
and heroin also extends to analgesics acting through delta 
and kappa receptors since these analgesics were not influenced 
by the antagonist. The possibility that M6G and heroin acted 
through traditional mu receptors also can be eliminated based 
upon their continued analgesic activity in mu opioid receptor 
knockout mice in which the first exon of MOR-1 had been 
targeted (A.G.P. Schuller, M. King, A. Chang, G W. Paster-
nak, J.E. Pintar, in preparation). These observations strongly 
support the presence of a novel receptor which is responsible 
for M6G and heroin analgesia and which is uniquely sensitive 
to 3-methoxynaltrexone. 
Although our results strongly suggest a novel receptor im-
portant in heroin actions, the pharmacology of heroin is com-
plex. Heroin is rapidly converted to 6-acetylmorphine, which 
also acts through the M6G receptor and is believed to mediate 
the actions of heroin. However, 6-acetylmorphine can be fur-
ther deacetylated to generate morphine [1], making it likely 
that heroin also has some morphine-like activity as well. It is 
likely that the rewarding properties of heroin, which are 
thought to be important for its addictive potential, are medi-
ated through the M6G receptor, but this remains to be dem-
onstrated. If the M6G receptor is responsible, the ability of 3-
methoxynaltrexone to selectively antagonize M6G actions in-
dicates that it may be possible to develop drugs which could 
selectively antagonize the addictive component of heroin ac-
tions, providing new therapeutic targets in the treatment of 
opioid abuse. 
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